|
Market Cap (19-May) $1,677,174,400 (454th) |
Close (30-Jun) $12.25 |
Volume (30-Jun) 261,029 |
Shortsold (5-May) 7,255,072 (5.76%) (39th) |
|
52w High $24.00 |
52w Low $8.61 |
P/E 77.52 |
EPS 1.09 |
NEU released this announcement to the ASX on 6 October 2021, 8:53. The announcement is marked as price sensitive, and is 2 page(s) in length and 125.58kb in size.
You can view all announcements from NEU and see how they appear on a price chart on the announcements page.
At the date of this announcement, NEU was 0.081% short sold according to ASIC data. It was ranked the 487th most shorted stock on the ASX. It is now ranked as the 39th most shorted stock on the ASX with 5.756% of total shares short sold as of the latest reported data (05 May 2025).
| Other Recent Announcements from NEU | |
|---|---|
| Neuren completes enrolment in Phelan-McDermid Phase 2 trial | 30 June 2023, 9:36 |
| Neuren opens first site in US for Prader-Willi Phase 2 trial | 28 June 2023, 9:55 |
| Change of Director's Interest Notice | 14 June 2023, 18:44 |
| $3.3 million raised from oversubscribed SPP | 6 October 2021, 8:53 |
| Feedback on Angelman IND and submission of Pitt Hopkins IND | 1 October 2021, 10:55 |
| IND application submitted for NNZ-2591 in Phelan-McDermid | 21 September 2021, 9:35 |
| Share Purchase Plan Offer Booklet | 17 September 2021, 9:28 |
You must be logged in to post a reply.
Neuren Pharmaceuticals 